FOXO3 and ovarian cancer: In conclusion, our study shows that LDFRT promotes the expression of FOXO3a and its downstream target PUMA, as well as reverses cisplatin resistance, suggesting that low‐dose fraction radiation may be served as an effective complementary adjuvant radiotherapy in the treatment of ovarian cancer.